Safety and practicality of high dose inhaled nitric oxide in emergency department COVID-19 patients
Strickland et al.,
Safety and practicality of high dose inhaled nitric oxide in emergency department COVID-19 patients,
The American Journal of Emergency Medicine, doi:10.1016/j.ajem.2022.04.052
Early terminated RCT with 47 ER patients in the USA, less than 12 days of symptoms, showing no significant difference in outcomes with a single high-dose administration of inhaled nitric oxide by mask, 250ppm for 30 min.
risk of mechanical ventilation, 178.9% higher, RR 2.79, p = 1.00, treatment 1 of 19 (5.3%), control 0 of 15 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
|
risk of hospitalization, 21.1% lower, RR 0.79, p = 1.00, treatment 1 of 19 (5.3%), control 1 of 15 (6.7%), NNT 71.
|
return to ER, 38.2% higher, RR 1.38, p = 0.72, treatment 7 of 19 (36.8%), control 4 of 15 (26.7%).
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Strickland et al., 4 May 2022, Randomized Controlled Trial, placebo-controlled, USA, peer-reviewed, 8 authors.
Contact:
brian.strickland@cuanschutz.edu.
Abstract: American Journal of Emergency Medicine 58 (2022) 5–8
Contents lists available at ScienceDirect
American Journal of Emergency Medicine
journal homepage: www.elsevier.com/locate/ajem
Safety and practicality of high dose inhaled nitric oxide in emergency
department COVID-19 patients
Brian Strickland, MD a,1,⁎, Lorenzo Albala, MD a, El Centro Coffey, MD a, Ryan W. Carroll, MD, MPH b,
Warren M. Zapol, MD c, Fumito Ichinose, MD, PhD d, Lorenzo Berra, MD d,e, N. Stuart Harris, MD, MFA a
a
Division of Wilderness Medicine, Department of Emergency Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, United States of America
Department of Pediatrics, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, United States of America
Anesthesia Center for Critical Care Research (ACCCR), Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, United States of America
d
Respiratory Care Service, Patient Care Services, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, United States of America
e
Surgical Intensive Care Unit, Department of Anesthesia, Critical Care and Pain Medicine (DACCPM), Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, United States of America
b
c
a r t i c l e
i n f o
Article history:
Received 25 October 2021
Received in revised form 5 April 2022
Accepted 29 April 2022
Keywords:
Nitric oxide
COVID-19
Emergency department
a b s t r a c t
Background: Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator and mild bronchodilator that has
been shown to improve systemic oxygenation, but has rarely been administered in the Emergency Department
(ED). In addition to its favorable pulmonary vascular effects, in-vitro studies report that NO donors can inhibit
replication of viruses, including SARS Coronavirus 2 (SARS-CoV-2). This study evaluated the administration of
high-dose iNO by mask in spontaneously breathing emergency department (ED) patients with respiratory symptoms attributed to Coronavirus disease 2019 (COVID-19).
Methods: We designed a randomized clinical trial to determine whether 30 min of high dose iNO (250 ppm)
could be safely and practically administered by emergency physicians in the ED to spontaneously-breathing patients with respiratory symptoms attributed to COVID-19. Our secondary goal was to learn if iNO could prevent
the progression of mild COVID-19 to a more severe state.
Findings: We enrolled 47 ED patients with acute respiratory symptoms most likely due to COVID-19: 25 of 47
(53%) were randomized to the iNO treatment group; 22 of 47 (46%) to the control group (supportive care
only). All patients tolerated the administration of high-dose iNO in the ED without significant complications or
symptoms. Five patients receiving iNO (16%) experienced asymptomatic methemoglobinemia (MetHb) > 5%.
Thirty-four of 47 (72%) subjects tested positive for SARS-CoV-2: 19 of 34 were randomized to the iNO treatment
group and 15 of 34 subjects to the control group. Seven of 19 (38%) iNO patients returned to the ED, while 4 of 15
(27%) control patients did. One patient in each study arm was hospitalized: 5% in iNO treatment and 7% in controls. One patient was intubated in the iNO group. No patients in either group died. The differences between these
groups were not significant.
Conclusion: A single dose of iNO at 250 ppm was practical and not associated with any significant adverse effects
when administered in the ED by emergency physicians...
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit